scholarly journals Indigenous way of hyperthermic intraperitoneal chemotherapy

2020 ◽  
Author(s):  
Rishin Dutta ◽  
Soumen Das ◽  
Makhan Lal Saha
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Stable Condition ◽  
Primary Objective ◽  
Peritoneal Surface Malignancy ◽  
Peritoneal Neoplasm ◽  
Resource Poor ◽  
Operative Recovery ◽  
Work Up

Introduction: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a form of highly concentrated, heated chemotherapy that is delivered directly to the abdomen intra-operatively. Currently for peritoneal surface malignancy (PSM), either primary or secondary from gastrointestinal (GI) or gynecologic cancers, cytoreductive surgery (CRS) combined with peri-operative HIPEC therapy is recommended. Aims & objectives: The primary objective of this case report is to show that in the current era of malignancy, resource poor centers can adopt our innovative way of HIPEC therapy and can treat peritoneal neoplasms which were considered to have only palliative treatment. Methods: After proper pre-operative work up, 61 year old lady diagnosed with adenocarcinoma of the sigmoid colon with peritoneal deposits was taken up for cytoreductive surgery and HIPEC. In the absence of a proper HIPEC machine, we used the hotline fluid warmer used by Anesthesiologists to heat the chemotherapy solution which was then re-circulated manually. Results: The patient had an excellent post-operative recovery and was discharged in a hemodynamically stable condition on post-operative day (POD) 6. She has completed 18 months of follow-up and has no signs of recurrence. Conclusions: To treat cancer like peritoneal neoplasm in resource-poor centers, the hotline machine can be a good option.

scholarly journals Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2471
Author(s):  
Philipp Horvath ◽  
Can Yurttas ◽  
Stefan Beckert ◽  
Alfred Königsrainer ◽  
Ingmar Königsrainer
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
University Hospital ◽  
Peritoneal Surface Malignancy ◽  
Treatment Protocols ◽  
Primary Tumors ◽  
Peritoneal Surface ◽  
Group 2 ◽  
Group 1

(1) Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provide survival benefits to selected patients. We aimed to report our experience and the evolution of our peritoneal surface malignancy program. (2) Methods: From June 2005 to June 2017, 399 patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at the Tübingen University Hospital were analyzed from a prospectively collected database. (3) Results: Peritoneal metastasis from colorectal cancer was the leading indication (group 1: 28%; group 2: 32%). The median PCI was 15.5 (range, 1–39) in group 1 and 11 (range, 1–39) in group 2 (p = 0.002). Regarding the completeness of cytoreduction (CC), a score of 0 was achieved in 63% vs. 69% for group 1 and 2, respectively (p = 0.010). Median overall survival rates for patients in group 1 and 2 for colon cancer, ovarian cancer, gastric cancer and appendix cancer were 34 and 25 months; 45 months and not reached; 30 and 16 months; 39 months and not reached, respectively. The occurrence of grade-III and -IV complications slightly differed between groups (14.5% vs. 15.6%). No 30-day mortality occurred. (4) Conclusions: Specialized centers are able to provide low-morbidity cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without mortality. Strict patient selection during the time period significantly improved CC scores.

scholarly journals Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms

2015 ◽  
Vol 22 (2) ◽  
pp. 100 ◽  
Author(s):  
P. Dubé ◽  
L. Sideris ◽  
C. Law ◽  
L. Mack ◽  
E. Haase ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Collaborative Group ◽  
Peritoneal Surface Malignancy ◽  
Access To Treatment ◽  
Peritoneal Surface ◽  
Appendiceal Neoplasms ◽  
Patient Representatives ◽  
Peritoneal Surface Malignancies

To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved.Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres.The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.

scholarly journals Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

BJS Open ◽  
2020 ◽  
Vol 5 (2) ◽  
Author(s):  
A Zahid ◽  
L Clarke ◽  
N Carr ◽  
K Chandrakumaran ◽  
A Tzivanakis ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Peritoneal Mesothelioma ◽  
Residual Tumour ◽  
Term Survival ◽  
Kaplan Meier ◽  
Peritoneal Neoplasm ◽  
Crs And Hipec

Abstract Background Multicystic peritoneal mesothelioma (MCPM) is a rare neoplasm, generally considered a borderline malignancy, best treated by cytoreductive surgery (CRS) to remove macroscopic disease, combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Owing to its rarity, little has been published on clinical presentation, clinical behaviour over time, or an optimal treatment approach. Methods A prospectively developed peritoneal malignancy database was interrogated for the years 2001–2018. Details on all patients with MCPM as a definitive diagnosis after CRS and HIPEC were analysed, including previous interventions, mode of presentation, surgical treatment, postoperative outcomes, and late follow-up information from abdominal CT and tumour markers. Results Some 40 patients with MCPM underwent CRS and HIPEC between 2001 and 2018. Of these, 32 presented with abdominal pain, distension or bloating, six patients presented with recurrence following previous surgery at the referring hospitals, and two had coincidental diagnoses during a surgical procedure. CRS involved peritonectomy in all 40 patients. Bowel resection was required in 18 patients, and seven had a temporary stoma. Thirty-eight patients were considered to have undergone a complete macroscopic tumour removal (completeness of cytoreduction CC0), and two had residual tumour nodules less than 2.5 mm in size, classified as CC1. Median duration of follow-up was 65 (range 48–79) months. There were no deaths during follow-up. The Kaplan–Meier-predicted recurrence-free interval was 115.4 months. Conclusion MCPM is a rare peritoneal neoplasm with a heterogeneous pattern of presentation. CRS and HIPEC is an effective management option for this group of patients, with favourable long-term survival.

scholarly journals Hyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young male

2021 ◽  
Vol 0 ◽  
pp. 1-5
Author(s):  
Rahul Sud ◽  
Arun Kumar Patra ◽  
Pradeep Jaiswal ◽  
Raj Mohan ◽  
P. K. Sindhu
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Survival Rates ◽  
Young Male ◽  
Temperature Management ◽  
Women Patients ◽  
Peritoneal Cancer ◽  
Operative Recovery

Primary peritoneal carcinomatosis (PPC) is a rare tumor, described in the literature almost exclusively in women. Patients with peritoneal carcinomatosis were considered incurable with low survival rates. This underwent a paradigm shift with hyperthermic intraperitoneal chemotherapy (HIPEC) after optimal cytoreductive surgery which changed the entire scenario. This case report describes the management of a 28-year-old male patient who was diagnosed to have PPC when he presented with massive ascites, who underwent cytoreductive surgery combined with HIPEC in our hospital. This procedure was complex for both the surgical team due to an extensive surgery, but also the anesthetist during the hyperthermic phase where the chemotherapy was administered. The post-operative recovery in such a case is also many times stormy and requires extreme vigilance. We had major challenges such as prolonged surgery, massive blood loss, temperature management, maintaining adequate urine output, and post-operative critical care. Extensive pre-operative preparation and proper coordination with the multidisciplinary team led us to handle the condition satisfactorily. The PPC in a young patient itself is a rare which enthuses us to report the case.

Sign in / Sign up

Export Citation Format

Share Document